Download PDF
Drug Res (Stuttg) 2018; 68(03): 139-145
DOI: 10.1055/s-0043-119068
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Renin Inhibition by Aliskiren Protects Rats Against Isoproterenol Induced Myocardial Infarction

Vasim Khan
1   Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
,
Md. Quamrul Hassan
1   Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
,
Mohd. Akhtar
1   Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
,
Abul Kalam Najmi
1   Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
› Author Affiliations
Further Information

Publication History

received 09 January 2017

accepted 22 August 2017

Publication Date:
04 October 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Objective Cardioprotective potential of aliskiren against isoproterenol-induced myocardial infarction was evaluated in this study.

Methods Wistar albino rats (n=36) were randomly divided into six groups. Normal control rats received 1 ml saline, orally for 14 days and 0.1 ml saline, subcutaneously on 13th and 14th treatment day while the toxic group animals were administered with saline orally for 14 days and isoproterenol (85 mg/kg, subcutaneously) on 13th and 14th day. In different pre-treatment groups, aliskiren (30, 50 & 100 mg/kg, orally) was administered for 14 days along with isoproterenol (85 mg/kg, subcutaneously) on the last two days. Per se group animals were given aliskiren (100 mg/kg orally) for 14 days. Twenty-four hours after the last drug treatment, cardiac marker enzymes (creatine kinase-MB and lactate dehydrogenase), apoptotic marker enzyme (caspase-3) and antioxidative enzymes (malondialdehyde, reduced glutathione, superoxide dismutase and catalase) were estimated, along with histopathological analysis of myocardium.

Results Isoproterenol treatment caused a significant increase in cardiac markers, malondialdehyde, and caspase-3 levels with a considerable decrease in reduced glutathione, superoxide dismutase and catalase enzyme levels. Aliskiren at 50 and 100 mg/kg doses significantly alleviated the increase of caspase-3 and cardiac marker enzymes as well as the changes in antioxidant enzymes, which was confirmed by histopathological analysis. Aliskiren (100 mg/kg) produced more pronounced protective effects than its other two doses. Moreover, the changes in per se group were insignificant as compared to normal control group.

Conclusion The present study thus provides an evidence for the protective effects of aliskiren in isoproterenol-induced myocardial infarction.

 

  • References

  • 1 Wang SB, Tian S, Yang F. et al. Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats. Eur J Pharmacol 2009; 615: 125-132
    CrossrefPubMedGoogle Scholar
  • 2 Gilski DJ, Borkenhagen B. Risk evaluation in action for cardiovascular health. Crit Care Nurse 2005; 25: 26-28
    CrossrefPubMedGoogle Scholar
  • 3 Brunner HR, Laragh JH, Baer L. et al. Essential hypertension: Renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449
    CrossrefPubMedGoogle Scholar
  • 4 Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105: 30A-35A
    PubMedGoogle Scholar
  • 5 Alderman MH, Ooi WL, Cohen H. et al. Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997; 10: 1-8
    CrossrefPubMedGoogle Scholar
  • 6 Alderman MH, Cohen HW, Sealey JE. et al. Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1-7
    CrossrefPubMedGoogle Scholar
  • 7 Rathore N, John S, Kale M. et al. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res 1998; 38: 297-303
    CrossrefPubMedGoogle Scholar
  • 8 Zhou R, Xu Q, Zheng P. et al. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 2008; 586: 244-250
    CrossrefPubMedGoogle Scholar
  • 9 Reid IA, Schrier RW, Earley LE. An effect of extrarenal beta adrenergic stimulation on the release of renin. J Clin Invest 1972; 51: 1861-1869
    CrossrefPubMedGoogle Scholar
  • 10 Heather LC, Catchpole AF, Stuckey DJ. et al. Isoproterenol induces in vivo functional and metabolic abnormalities: Similar to those found in the infarcted rat heart. J Physiol Phramacol 2009; 60: 31-39
    PubMedGoogle Scholar
  • 11 Devika PT, Stanely Mainzen Prince P. Protective effect of (-)-epigallocatechin-gallate (EGCG) on lipid peroxide metabolism in isoproterenol induced myocardial infarction in male Wistar rats: A histopathological study. Biomed Pharmacother 2008; 62: 701-708
    CrossrefPubMedGoogle Scholar
  • 12 Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens 1997; 6: 28-34
    CrossrefPubMedGoogle Scholar
  • 13 Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999; 33: S21-S28
    CrossrefPubMedGoogle Scholar
  • 14 Buczko W, Kramkowski K, Mogielnicki A. Are the endothelial mechanisms of ACE-Is already established?. Pharmacol Rep 2006; 58: 126-131
    PubMedGoogle Scholar
  • 15 Gaddam KK, Oparil S. Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients?. Curr Opin Nephrol Hypertens 2008; 17: 484-490
    CrossrefPubMedGoogle Scholar
  • 16 Nussberger J, Wuerzner G, Jensen C. et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP 100): comparison with enalapril. Hypertension 2002; 39: E1-E8
    CrossrefPubMedGoogle Scholar
  • 17 Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003; 21: 1599-1608
    CrossrefPubMedGoogle Scholar
  • 18 Lakkis J, Lu WX, Weir MR. RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003; 5: 408-417
    CrossrefPubMedGoogle Scholar
  • 19 Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: Do we need a more comprehensive strategy?. Rev Cardiovasc Med 2006; 7: 45-54
    PubMedGoogle Scholar
  • 20 Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008; 51: 519-528
    CrossrefPubMedGoogle Scholar
  • 21 Wood JM, Maibaum J, Rahuel J. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705
    CrossrefPubMedGoogle Scholar
  • 22 Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-1456
    CrossrefPubMedGoogle Scholar
  • 23 Nussberger J. Renin inhibitors. In: Oparil S, Weber MA. eds. Hypertension, A Companion to Brenner and Rector’s, The kidney. Second edition Elsevier; 2005: 754-764
    Google Scholar
  • 24 Brown MJ. Aliskiren. Circulation 2008; 118: 773-784
    CrossrefPubMedGoogle Scholar
  • 25 Westermann D, Riad A, Lettau O. et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008; 52: 1068-1075
    CrossrefPubMedGoogle Scholar
  • 26 Soloman SD, Appelbaum E, Manning WJ. et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537
    CrossrefPubMedGoogle Scholar
  • 27 Goyal S, Arora S, Mittal R. et al. Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction. Eur J Pharmacol 2009; 619: 75-84
    CrossrefPubMedGoogle Scholar
  • 28 Young DS. Effects of drugs on clinical laboratory tests. AACC Press 1990; 120-122
    PubMedGoogle Scholar
  • 29 Lum G, Gambino SR. A comparison of serum versus heparinized for routine chemistry tests. Am J Clin Pathol 1974; 61: 108-113
    CrossrefPubMedGoogle Scholar
  • 30 Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358
    CrossrefPubMedGoogle Scholar
  • 31 Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25: 192-205
    CrossrefPubMedGoogle Scholar
  • 32 Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47: 469-474
    CrossrefPubMedGoogle Scholar
  • 33 Claiborne A. Catalase activity. In: Greenwald RA. eds. Handbook of methods of oxygen free radical research. Boca Raton: CRC Press; 1985: 283-284
    Google Scholar
  • 34 Lowry OH, Rosebrough NJ, Farr AL. et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 35 Gurtu V, Kain SR, Zhang G. Fluorometric and colorimetric detection of caspase activity associated with apoptosis. Anal Biochem 1997; 251: 98-102
    CrossrefPubMedGoogle Scholar
  • 36 Suchalatha S, Shyamala Devi CS. Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol. Indian J Exp Biol 2004; 42: 174-178
    PubMedGoogle Scholar
  • 37 Suchalatha S, Thirugnanasambandam P, Maheswaran E. et al. Role of Arogh, a polyherbal formulation to mitigate oxidative stress in experimental myocardial infarction. Indian J Exp Biol 2004; 42: 224-226
    PubMedGoogle Scholar
  • 38 Grimm D, Elsner D, Schunkert H. et al. Development of heart failure following isoproterenol administration in the rat: Role of the renin-angiotensin system. Cardiovasc Res 1994; 37: 91-100
    PubMedGoogle Scholar
  • 39 Matzdorf C, Kurtz A, Hocherl K. COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidenys. Am J Physiol Renal Physiol 2007; 292: F1782-F1790
    CrossrefPubMedGoogle Scholar
  • 40 Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006; 7: 3-14
    CrossrefPubMedGoogle Scholar
  • 41 Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. Clin Ther 2007; 29: 1803-1824
    CrossrefPubMedGoogle Scholar
  • 42 Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008; 60: 623-631
    PubMedGoogle Scholar
  • 43 Ferrario CM. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: Antihypertensive effects and benefits beyond BP control. Life Sci 2010; 86: 289-299
    CrossrefPubMedGoogle Scholar
  • 44 Angeli F, Reboldi G, Mazzotta G. et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf 2012; 7: 76-85
    CrossrefPubMedGoogle Scholar
  • 45 Fleetwood G, Boutinet S, Meier M. et al. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J Cardiovasc Pharmacol 1991; 17: 351-356
    CrossrefPubMedGoogle Scholar
  • 46 Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 1974; 71: 3400-3404
    CrossrefPubMedGoogle Scholar
  • 47 Gutteridge JM. The role of superoxide and hydroxyl radicals in phospholipid peroxidation catalysed by iron salts. FEBS Lett 1982; 150: 454-458
    CrossrefPubMedGoogle Scholar
  • 48 Zhou B, Wu LJ, Li LH. et al. Silibinin protects against isoproterenol-induced rat cardiac myocyte injury through mitochondrial pathway after up-regulation of SIRT1. J Pharmacol Sci 2006; 102: 387-395
    CrossrefPubMedGoogle Scholar
  • 49 Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacol Ther 2001; 89: 187-206
    CrossrefPubMedGoogle Scholar
  • 50 Sawyer DB, Siwik DA, Xiao L. et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-388
    CrossrefPubMedGoogle Scholar
  • 51 Wu J, Hecker JG, Chiamvimonvat N. et al. Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev 2009; 61: 351-363
    CrossrefPubMedGoogle Scholar
  • 52 Hegstad AC, Ytrehus K, Myklebust R. et al. Ultrastructural changes in myocardial myocytic mitochondria: Crucial step in the development of oxygen radical-induced damage in isolated rat hearts?. Basic Res Cardiol 1994; 89: 128-138
    PubMedGoogle Scholar
  • 53 Hu A, Jiao X, Gao E. et al. Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress. J Pharmacol Exp Ther 2006; 318: 469-475
    CrossrefPubMedGoogle Scholar
  • 54 Li H, Xie YH, Yang Q. et al. Cardioprotective effect of paeonol and danshensu combination on isoproterenol-induced myocardial injury in rats. PLOS One 2012; 7: e48872
    CrossrefPubMedGoogle Scholar